Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

Autor: Germana Tognon, Michel Fabbro, Ursula A. Matulonis, Kathleen N. Moore, Susana Banerjee, Mansoor Raza Mirza, Philippe Follana, Kristina Hellman, Philipp Harter, Ronnie Shapira-Frommer, Sven Mahner, Isabel Bover, Sebastien Hazard, Mario Javier Pineda, Diane Provencher, Isabel Palacio Vázquez, Robert M. Wenham, Anne Dørum, Frédéric Goffin, Anna V. Tinker

Publikováno v: Gynecologic Oncology
Gynecologic Oncology, Elsevier, 2019, 152, pp.560-567. ⟨10.1016/j.ygyno.2018.12.009⟩

Objective. To analyze the safety and efficacy of niraparib in patients aged >= 70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial. Methods. The trial enrolled 2 independent cohorts with histologically diagnosed recurrent ovarian, fal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb9ad9c2c774b562481bb27f33aac39c
https://doi.org/10.1016/j.ygyno.2018.12.009

Laboratory cross-comparison of tumor BRCA1/2 analysis in a multicenter epithelial ovarian cancer series: The BORNEO GEICO60-0 study

Autor: Alejandro Gallego, Cristina Perez Segura, Juan Cueva, Zaida García-Casado, Ignacio A. Romero, Alfonso Yubero Esteban, Isabel Palacio Vázquez, Judit Matito, Ana Beatriz Sanchez, Lorena Fariñas-Madrid, Ana Vivancos, Jesus Alarcon, Ana Oaknin, Andres Poveda, Jose Antonio Lopez Guerrero, Raul Marquez, Maria Pilar Barretina-Ginesta

Publikováno v: JOURNAL OF CLINICAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Publons
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

6055 Background: Epithelial ovarian cancer (EOC) identification of BRCA1 and BRCA2 mutations is usually carried out in germline, representing around 17% in high grade serous ovarian cancer (HGSOC) and further 5-7% are only identified in the tumor (so

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcee1ff10eb4c2a378851890f04ca90e
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9128

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Autor: Giovanni Scambia, Josep M. del Campo, Isabel Palacio Vázquez, Susana Banerjee, Véronique D'Hondt, Benedict B. Benigno, Mansoor Raza Mirza, Jonathan S. Berek, Susanne Malander, Felix Hilpert, Anna V. Tinker, Shefali Agarwal, Diane Provencher, Bente Lund, Ursula A. Matulonis, Stacie Hudgens, Joseph Buscema, Jalid Sehouli, Amit M. Oza, Dominique Berton-Rigaud

Publikováno v: Lancet Oncology
Lancet Oncology, Elsevier, 2018, 19 (8), pp.1117-1125. ⟨10.1016/S1470-2045(18)30333-4⟩
Oza, A M, Matulonis, U A, Malander, S, Hudgens, S, Sehouli, J, Del Campo, J M, Berton-Rigaud, D, Banerjee, S, Scambia, G, Berek, J S, Lund, B, Tinker, A V, Hilpert, F, Vázquez, I P, D'Hondt, V, Benigno, B, Provencher, D, Buscema, J, Agarwal, S & Mirza, M R 2018, ' Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA) : results from a double-blind, phase 3, randomised controlled trial ', The Lancet. Oncology, vol. 19, no. 8, pp. 1117-1125 . https://doi.org/10.1016/S1470-2045(18)30333-4

Summary Background Quality of life (QOL) has become an important complementary endpoint in cancer clinical studies alongside more traditional assessments (eg, tumour response, progression-free survival, overall survival). Niraparib maintenance treatm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79737108041416b019aa4999a7495fed
https://hal.umontpellier.fr/hal-02283098